BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
- Presentation available September 11, 2023 on BGBIO website -
BERGEN, Norway, September 11, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for Non-Small Cell Lung Cancer (NSCLC), announced today that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference held in New York City, September 11-13, 2023.
Chief Executive Officer Martin Olin will provide an update on BerGenBio including a review of clinical data substantiating the role of selective AXL inhibition with its lead molecule bemcentinib in cancer and describing on-going activities in the treatment of first line metastatic NSCLC patients with STK11 mutations – a known prognostic factor in poorer response to current standard of care therapies.
The presentation used in the webcast will be uploaded to the investor section of the Company’s website www.bergenbio.com/investors/presentations at time of presentation, September 11, 7.00am ET (13:00 CEST).
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.